Abstract: Compositions and methods for using programmable DNA binding proteins to increase the efficiency and/or specificity of targeted genome modification or to facilitate the detection of specific genomic loci in eukaryotic cells.

Abstract: Provided in the present invention are a magnetic resonance imaging system and method, and a computer-readable storage medium. The method comprises: performing a medical scan of a subject and acquiring a first medical image having a first noise interference artifact, and performing an additional scan of the subject to acquire a second medical image, wherein the second medical image has a second noise interference artifact, and the location mapping of the second noise interference artifact in the first medical image is symmetrical to the location of the first noise interference artifact relative to a pixel center of the first medical image; and performing synthesis-related processing on the first medical image and the second medical image to acquire a post-processed image with reduced noise interference artifacts.

Abstract: This disclosure provides methods and compositions for improving the genome modification efficiency of programmable DNA modification proteins during transfection (e.g., electroporation).

Abstract: Compositions and methods for using nucleosome interacting protein domains to increase accessibility of programmable DNA modification proteins to target chromosomal sequences, thereby increasing efficiency of targeted genome/epigenetic modification in eukaryotic cells.

Abstract: Various methods and systems are provided for automatically registering and stitching images. In one example, a method includes entering a first image of a subject and a second image of the subject to a model trained to output a transformation matrix based on the first image and the second image, where the model is trained with a plurality of training data sets, each training data set including a pair of images, a mask indicating a region of interest (ROI), and associated ground truth, automatically stitching together the first image and the second image based on the transformation matrix to form a stitched image, and outputting the stitched image for display on a display device and/or storing the stitched image in memory.

Abstract: Compositions and methods for using programmable DNA binding proteins to increase the efficiency and/or specificity of targeted genome modification or to facilitate the detection of specific genomic loci in eukaryotic cells.

Abstract: Compositions and methods for using nucleosome interacting protein domains to increase accessibility of programmable DNA modification proteins to target chromosomal sequences, thereby increasing efficiency of targeted genome/epigenetic modification in eukaryotic cells.

Abstract: Engineered Cas9 systems are disclosed herein.

Abstract: Engineered Cas9 systems are disclosed herein.

Abstract: Various methods and systems are provided for automatically registering and stitching images. In one example, a method includes entering a first image of a subject and a second image of the subject to a model trained to output a transformation matrix based on the first image and the second image, where the model is trained with a plurality of training data sets, each training data set including a pair of images, a mask indicating a region of interest (ROI), and associated ground truth, automatically stitching together the first image and the second image based on the transformation matrix to form a stitched image, and outputting the stitched image for display on a display device and/or storing the stitched image in memory.

Abstract: Engineered Cas9 protein variants and systems, nucleic acids encoding said protein variants and systems, and methods of making and using said protein variants and systems for genome modification.

Abstract: Provided in the present invention are a magnetic resonance imaging system and method, and a computer-readable storage medium. The method comprises: performing a medical scan of a subject and acquiring a first medical image having a first noise interference artifact, and performing an additional scan of the subject to acquire a second medical image, wherein the second medical image has a second noise interference artifact, and the location mapping of the second noise interference artifact in the first medical image is symmetrical to the location of the first noise interference artifact relative to a pixel center of the first medical image; and performing synthesis-related processing on the first medical image and the second medical image to acquire a post-processed image with reduced noise interference artifacts.

Abstract: Provided in the present application are a target area determination method and a medical imaging system, specifically a target area determination method and device, a medical imaging system, and a non-transitory computer-readable storage medium. The target area determination method includes: pre-processing an original image to acquire a pre-processed medical image, acquiring a target point in the medical image, and acquiring a plurality of sectional images of the medical image according to the target point, and acquiring, on the basis of a first model, a target area corresponding to the target point in the plurality of sectional images.

Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.

Abstract: Disclosed is a method of removing volatile organic compounds from sponges by using supercritical/subcritical fluid, The method includes the following steps: placing the sponge block to be treated in the extraction kettle; feeding the critical flow medium into the extraction kettle; performing extraction under the supercritical or subcritical conditions of the critical flow medium; releasing pressure to normal pressure after extraction; and separating to obtain devolatilized sponge. The volatile removal device used in the disclosure is a supercritical extraction equipment, which can adopt static extraction or dynamic extraction or a combination of the two. CO2 releases pressure in the separating kettle after contacting the sponge to be treated in the device for mass transfer for a certain period, when the static extraction devolatilization is carried out.

Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.

Abstract: The present invention provides methods for modifying chromosomal sequences. In particular, methods are provided for using RNA-guided endonucleases or modified RNA-guided endonucleases to modify targeted chromosomal sequences.

Abstract: Engineered Cas9 systems are disclosed herein.

Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.

Abstract: Engineered Cas9 systems are disclosed herein. For example, Cas9-marker fusion proteins are provided. Peptide linkers which facilitate fusion of heterologous proteins to CRISPR proteins in ways that preserve CRISPR functionality are also provided.